Clinical

On this episode of Managed Care Cast, we highlight a new feature on AJMC.com, the website of The American Journal of Managed Care®, called Clinical Spotlight, where our editors provide a series of interviews with leading experts in certain specialties.

Novartis' drug, which combines sacubitril and valsartan, is the first to directly treat patients with heart failure with preserved ejection fraction.

Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.

Older adults with acute myeloid leukemia (AML) saw increased overall and relapse-free survival, as well as preserved quality of life, following oral administration of 300-mg azacitidine.

Genentech's tiragolumab, a novel immunotherapy for non-small cell lung cancer with PD-L1 expression, is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation.

Ohio dermatologist Matthew J. Zirwas, MD, offers his view on what step therapy would look like in patients with atopic dermatitis.

Abatacept was shown to have a 9% increase in likelihood of achieving remission compared with conventional therapy for rheumatoid arthritis (RA), which the researchers contribute to the treatment’s lower discontinuation rates.

Patients being treated for multiple myeloma with carfilzomib should have cardiopulmonary screening and monitoring due to the risk of developing pulmonary arterial hypertension (PAH).

In the placebo-controlled trial, 86% of participants who received semaglutide attained at least a 5% reduction in total body weight.

Mortality risk stratification can identify patients at higher risk of mortality and readmissions for prevention strategies. Other patients should be the focus of length-of-stay reduction strategies.

A new study assessed the genomic alterations identified by ctDNA analysis compared with tissue-based comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer.

Breast cancer oncologists explore more recent advances using oral chemotherapies to treat metastatic breast cancer.

Results from a new clinical trial suggest that discontinuation of tyrosine kinase inhibitors (TKIs) is safe, feasible and is associated with improvements in patient-related outcomes (PROs) in chronic myeloid leukemia (CML).

Noting each of their benefits, the researchers also caution that to better characterize their safety and efficacy, there’s a need for further investigation among larger patient pools.

A recent study took a look at the use of biologics for generalized pustular psoriasis, a rare, potentially life-threatening inflammatory disorder.

Results from the phase 3 PRECISE trial showed that MRI with targeted biopsies matched or exceeded the accuracy of the current standard for detecting clinically significant prostate cancer.

A CAR T-cell therapy that promises fewer side effects, and possibly lower hospital costs, wins approval after lengthy delays.

Data from nearly 3000 patients across multiple countries with the disease showed that undertreatment was most notable among patient with hemoglobin (Hb) <10 g/dL.

Temperature and transepidermal water loss can serve as objective measures to help determine severity of cases of atopic dermatitis (AD) psoriasis and identify which patients need intensive treatment, according to a new study.

Vamshi Rao, MD, attending physician of Neurology at Ann and Robert H. Lurie Children’s Hospital of Chicago, discusses how disease modifying therapies have improved spinal muscular atrophy (SMA) prognosis.

Shortening a traditional 45-day course of radiation therapy to 5 days of stereotactic body radiotherapy for patients with advanced, high-risk prostate cancer is safe and effective, a study from UCLA Jonsson Comprehensive Cancer Center found.

An engineered lentivirus was created to avoid some of the drawbacks associated with current gene therapy vectors for sickle cell disease (SCD) and beta-thalassemia.

Johnson & Johnson, Novavax, release positive results from phase 3 trials on their respective coronavirus disease 2019 (COVID-19) vaccines; report indicates undercounted nursing home deaths in New York; experts push for improved mask practices.

Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing patients with the condition.

Voclosporin, the first FDA-approved oral therapy for lupus nephritis, will be sold as Lupkynis by Aurinia Pharmaceuticals and is approved for use in conjunction with immunosuppressive treatment.

Recently published results show that adding a limited course of chemotherapy to nivolumab plus ipilimumab in the first-line setting for non-small cell lung cancer is effective and tolerable.

A recent review explores the use of biologics in atopic and inflammatory conditions as well as lingering research gaps.

Florida Cancer Specialists has integrated SpaceOAR Hydrogel into its armamentarium as a pre-treatment for radiation therapy in prostate cancer patients.

Mepolizumab and benralizumab are both potent targets of the interlukin-5 pathway with the ability to significantly reduce eosinophil counts, according to new research published in Allergy, Asthma & Clinical Immunology.

Investigators using real-world data found that patients receiving treatment from slow mist inhalers (SMIs) had fewer exacerbations and hospitals readmissions compared with patients using dry powder inhalers (DPIs).